

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

SCN1A RABBIT PAB

Cat.#: S220369

Product Name: Anti-SCNIA Rabbit Polyclonal Antibody

Synonyms: FEB3; FHM3; NAC1; SCN1; SMEI; EIEE6; FEB3A; HBSCI; GEFSP2; Nav1.1

UNIPROT ID: P35498 (Gene Accession - NP_001159435)

Background: The vertebrate sodium channel is a voltage-gated ion channel essential for the generation and propagation of action potentials, mainly in nerve and muscle. Voltage-sensitive sodium channels are heteromeric complexes consisting of a large central pore-forming glycosylated alpha subunit, and two smaller auxiliary beta subunits. This gene encodes the large alpha subunit, and mutations in this gene have been associated with several epilepsy, convulsion and migraine disorders. Alternative splicing results in multiple transcript variants. The RefSeq Project has decided to create four representative RefSeq records. Three of the transcript variants are supported by experimental evidence and the fourth contains alternate 5' untranslated exons, the exact combination of which have not been experimentally confirmed for the full-length transcript.

Immunogen: Synthetic peptide of human SCNIA

Applications: ELISA, IHC

Recommended Dilutions: IHC: 25-100; ELISA: 5000-10000

Host Species: Rabbit

Clonality: Rabbit Polyclonal

Isotype: Immunogen-specific rabbit IgG

Purification: Antigen affinity purification

Species Reactivity: Human, Rat

Constituents: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

Research Areas: Neuroscience

Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing



Immunohistochemistry analysis of paraffin embedded Human prostate cancer tissue using 220369(SCNIA Antibody) at a dilution of 1/20(Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human prostate cancer tissue is first treated with the synthetic peptide and then with 220369(Anti-SCN1A Antibody) at dilution 1/20.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010